Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Peerj
|
November 26, 2020
Machine learning prediction of motor response after deep brain stimulation in Parkinson's disease-proof of principle in a retrospective cohort
Jeroen G V Habets, Marcus L F Janssen, Annelien A Duits, et al.
Neuromodulation : Journal of the International Neuromodulation Society
|
February 7, 2022
Cognitive Outcome After Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder: A Systematic Review
Tim A M Bouwens van der Vlis, Annelien Duits, Mégan M G H van de Veerdonk, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 22, 2021
Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial
Anja J H Moonen, Anne E P Mulders, Luc Defebvre, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum
|
January 6, 2001
Precancerous lesions in the kidney
H Van Poppel, S Nilsson, F Algaba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
Brain Stimulation
|
August 9, 2022
Multimodal multi-center analysis of electroconvulsive therapy effects in depression: Brainwide gray matter increase without functional changes
L A van de Mortel, W B Bruin, R M Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2002
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
M Marchand, C J A Punt, S Aamdal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Peerj
|
November 26, 2020
Machine learning prediction of motor response after deep brain stimulation in Parkinson's disease-proof of principle in a retrospective cohort
Jeroen G V Habets, Marcus L F Janssen, Annelien A Duits, et al.
Neuromodulation : Journal of the International Neuromodulation Society
|
February 7, 2022
Cognitive Outcome After Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder: A Systematic Review
Tim A M Bouwens van der Vlis, Annelien Duits, Mégan M G H van de Veerdonk, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 22, 2021
Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial
Anja J H Moonen, Anne E P Mulders, Luc Defebvre, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum
|
January 6, 2001
Precancerous lesions in the kidney
H Van Poppel, S Nilsson, F Algaba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
Brain Stimulation
|
August 9, 2022
Multimodal multi-center analysis of electroconvulsive therapy effects in depression: Brainwide gray matter increase without functional changes
L A van de Mortel, W B Bruin, R M Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2002
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
M Marchand, C J A Punt, S Aamdal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 3